Topics

Investigators Assess PARP Inhibitor-Abiraterone Combo as Frontline mCRPC Therapy

10:54 EDT 15 Aug 2019 | OncLive

Seeking to explore an apparent synergy between agents, investigators are evaluating the PARP inhibitor olaparib in combination with the hormone blocker abiraterone in men with metastatic castration-resistant prostate cancer who have received no prior cytotoxic chemotherapy or new hormonal agents.

Original Article: Investigators Assess PARP Inhibitor-Abiraterone Combo as Frontline mCRPC Therapy

NEXT ARTICLE

More From BioPortfolio on "Investigators Assess PARP Inhibitor-Abiraterone Combo as Frontline mCRPC Therapy"

Quick Search

Relevant Topics

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...